|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
The Intensified Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
|
Russell Szmulewitz, MD
Russell Szmulewitz joins Charles Ryan in a discussion highlighting three abstracts in the metastatic hormone-sensitive prostate cancer treatment landscape when discussing treatment intensification. In highlighting these studies, he outlines five key questions for the field of mHSPC.
|
|
|
|
|
|
|
|
|
|
|
|
8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial
|
Gwenaëlle Gravis Mescam, MD
Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC).
|
|
|
|
|
|
|
|
|
|
|
|
The Association of PSA Response and Overall Survival in Patients with mHSPC in the Phase 3 ARASENS Trial
|
Fred Saad, MD, FRCS
Fred Saad joins Alicia Morgans in discussing the association between PSA response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.
|
|
|
|
|
|
|
|
|
|
|
|
Treatment of Vulnerable/Frail Patients with mHSPC - APCCC 2022 Presentation
|
|
Alicia Morgans, MD, MPH
|
| At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Alicia Morgans presents on the treatment of vulnerable/frail patients with metastatic hormone-sensitive prostate cancer (mHSPC).
|
|
|
|
|
|
|
|
|
|
|
|
| Making Sense of the Intensified mHSPC Landscape - Discussion |
| Russell Z. Szmulewitz, MD |
| The 2022 ASCO annual meeting featured an oral abstract session on prostate cancer, including a discussant presentation by Dr. Russell Szmulewitz discussing making sense of the intensified mHSPC landscape. As part of this discussant presentation, Dr. Szmulewitz highlighted three abstracts and outlines five key questions for the field of mHSPC. |
|
|
|
|
|
| Metastatic Castration-Sensitive Prostate Cancer 2022 Updates - Discussion
|
| Boris A. Hadaschik, MD
|
| The 2022 ESMO annual meeting featured a prostate cancer session, including a discussant presentation by Boris Hadaschik discussing two abstracts, including “Differential treatment response with nodal metastases in mHSPC and evaluation of nodal burden as a prognostic biomarker -ancillary studies of the docetaxel and abiraterone acetate and prednisolone phase III trials from STAMPEDE” presented by Áine Haran, and “8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase 3 trial” presented by Gwenaelle Gravis Mescam.
|
|
|
|
|
|
|
|
|
|
|
| 8-Month PSA Strongly Predicts Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial
|
| Gwenaelle Gravis Mescam
|
| In this presentation, Gwenaelle Mescam discusses the 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC) in the PEACE-1 phase 3 trial. Dr. Mescam and colleagues assessed the association of 8-month PSA value with rPFS and OS in mCSPC men treated in PEACE-1 with the triplet systemic association: ADT+ docetaxel + abiraterone acetate + prednisone.
|
|
|
|
|
|
| Overall Survival With Darolutamide Versus Placebo in Combination With Docetaxel and Androgen-Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in the Phase 3 ARASENS Trial
|
| Matthew R. Smith, MD, Ph.D.
|
| In this presentation, Dr. Smith presented the results of the ARASENS study. ARASENS is a randomized phase 3 trial of darolutamide versus placebo in combination with docetaxel and androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC).
|
|
|
|
|
|
| Updated Overall Survival Outcomes in ENZAMET (ANZUP 1304), an International, Cooperative Group Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
| Ian D. Davis, Ph.D., MBBS, FRACP, FAChPM |
| The addition of enzalutamide to testosterone suppression in mHSPC confers an overall survival benefit. Interestingly, the median overall survival of patients in this study in the control arm who received docetaxel was quite long at over 60 months. One hypothesis is that these patients were taken off study early and had prompt initiation of second generation anti-androgen therapy. The greatest benefit of triplet therapy appears to be relatively early in the disease course for patients with synchronous high-volume metastatic disease. |
|
|
|
|
|
| A Phase 3 Trial of SHR3680 Versus Bicalutamide in Combination With ADT in Patients With High-Volume mHSPC |
| Ding-Wei Ye, MD, Ph.D. |
| The 2022 ASCO annual meeting featured an oral abstract session on prostate cancer, including a presentation by Dr. Ding-Wei Ye discussing the phase 3 trial of SHR3680 versus bicalutamide in combination with ADT in patients with high-volume mHSPC. |
|
|
|
|
|
| Assessing Intermediate Clinical Endpoints As Potential Surrogates for Overall Survival in Men With mHSPC |
| Susan Halabi, Ph.D. |
| Susan Halabi discusses the intermediate clinical endpoints as potential surrogates for overall survival in men with mHSPC. Overall survival is the gold standard endpoint in oncology trials, however clinical trials in mHSPC with OS as a primary endpoint take close to a decade to read out. |
|
|
|
|
|
|
